Evolus (EOLS) Releases Favorable Dermal Fillers Study Data [Yahoo! Finance]
Evolus, Inc. (EOLS)
Last evolus, inc. earnings: 2/25 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
us.evolis.com/investor-relations
Company Research
Source: Yahoo! Finance
Presented at the 2024 SCALE Meeting, these results represent a significant milestone in the company's strategic expansion within the aesthetic device market. These promising results bolster the company's upcoming Premarket Approval Application (“PMA”) for the U.S. launch of Evolus's dermal filler lines. Evolus plans to submit the PMA applications for Evolysse Lift and Smooth within 90 days. Strategic Significance The addition of Evolysse fillers to the company's portfolio will perfectly complement Evolus' flagship neurotoxin Jeuveau, which claims to be the fastest growing neurotoxin in the United States for the past three years. Evolysse with Jeuveau is projected to increase Evolus' total addressable market by 78%. This expansion positions Evolus as a more formidable player in the aesthetics sector, catering to a broader range of consumer needs. The company in this regard emphasized the consistency of the U.S. study results with previous European trials, enhancing confidence
Show less
Read more
Impact Snapshot
Event Time:
EOLS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EOLS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EOLS alerts
High impacting Evolus, Inc. news events
Weekly update
A roundup of the hottest topics
EOLS
News
- Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain [Yahoo! Finance]Yahoo! Finance
- Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in SpainBusiness Wire
- Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- AEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction Plan [Yahoo! Finance]Yahoo! Finance
- Over 130 Resident Dermatologists Receive In-Depth Cosmetic Training From Renowned ASDS Member Physicians [Yahoo! Finance]Yahoo! Finance
EOLS
Earnings
- 5/7/24 - Miss
EOLS
Sec Filings
- 6/11/24 - Form 8-K
- 6/6/24 - Form 4
- 6/6/24 - Form 144
- EOLS's page on the SEC website